G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/574 (2006.01) C12Q 1/68 (2006.01)
Patent
CA 2707886
Provided herein are the biomarkers for monitoring the treatment by immunomodulatory compounds. The use of biomarkers such as SPARC, p21, and cyclin DI mRNA or protein levels as biomarkers to predict whether an immunomodulatory compound is likely to be successful in treating certain types of cancer, such as NHL, is also provided. Further, the expression of these genes or proteins can be used to monitor progress of treatment effectiveness and patient compliance in cancer patients that are receiving treatment with immunomodulatory compounds.
L'invention propose des biomarqueurs pour surveiller le traitement par des composés immunorégulateurs. L'invention propose également l'utilisation de biomarqueurs, tels que SPARC, p21, et de taux d'ARNm ou de protéine cycline D1 en tant que biomarqueurs pour prédire si un composé immunorégulateur est susceptible de réussir à traiter certains types de cancers, tels qu'un lymphome non hodgkinien. En outre, l'expression de ces gènes ou protéines peut être utilisée pour surveiller le progrès de l'efficacité du traitement et l'observance du patient chez des patients atteints de cancer qui reçoivent un traitement avec des composés immunorégulateurs.
Bartlett J. Blake
Schafer Peter H.
Zhang Ling-Hua
Celgene Corporation
Smart & Biggar
LandOfFree
Biomarkers for predicting the sensitivity of cells to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biomarkers for predicting the sensitivity of cells to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for predicting the sensitivity of cells to... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1427809